Garadacimab-gxii is the first FDA-approved factor XIIa inhibitor for hereditary angioedema, offering a once-monthly prophylactic treatment option. The VANGUARD trial showed an 87% reduction in HAE ...

- ANDEMBRY®, the first and only once-monthly treatment targeting factor XIIa to prevent attacks in HAE patients, inhibits plasma protein factor XIIa, which initiates the cascade of events leading to ...

Possible differential diagnoses for hereditary angioedema (HAE) include acquired angioedema with low C1 inhibitor enzyme (AAE-C1-INH), angiotensin-converting enzyme (ACE) inhibitor-induced angioedema ...

Hereditary angioedema (HAE) is a rare, autosomal dominant disorder defined by episodic, potentially life‐threatening swellings that can affect the skin, gastrointestinal tract, and upper airways.

To diagnose hereditary angioedema (HAE), doctors will run a series of blood tests as well as genetic testing if needed. Hereditary angioedema (HAE) is a genetic condition that causes episodes of ...